A Phase 1b, Multicenter, Open-Label, Single-arm Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) in Participants Aged 12 to 75 Years for the Treatment of Focal-Onset Seizures
Latest Information Update: 10 Dec 2025
At a glance
- Drugs Cannabidiol (Primary)
- Indications Seizures
- Focus Therapeutic Use
- Sponsors Jazz Pharmaceuticals Inc
Most Recent Events
- 08 Dec 2025 Status changed from not yet recruiting to recruiting.
- 26 Nov 2025 New trial record